<DOC>
	<DOCNO>NCT02622958</DOCNO>
	<brief_summary>The purpose study determine whether PH94B nasal spray effective Acute Treatment symptoms Social Anxiety Disorder ( SAD ) adult men woman . The hypothesis PH94B nasal spray ( .8 microgram ) rapid onset efficacy improve performance interaction anxiety patient diagnose Social Anxiety Disorder ( SAD ) .</brief_summary>
	<brief_title>Feasibility Study PH94B Nasal Spray Acute Treatment Social Anxiety Disorder ( SAD )</brief_title>
	<detailed_description>The study randomize , double-blind , placebo-controlled , 2-way crossover trial efficacy safety PH94B treatment subject diagnose Social Anxiety Disorder define Diagnostic Statistical Manual IV confirm MINI ( 5.0.0 ) . The study intend serve feasibility trial multi-center phase 3 study protocol similar design . The primary objective study evaluate design feature large Phase 3 study evaluate safety efficacy PH94B acute management symptom subject Social Anxiety Disorder . Careful review diary entry measurement study medication compliance week use determine feasibility use study medication `` need '' basis anxiety-provoking social event . Specifically , frequency use , variability SUDS rating , effect size difference average peak SUDS rating treatment PH94B placebo , general reliability diary record method evaluate used refine inclusion exclusion criterion well provide guidance design large multi-site study . The study last total 6-8 week . The randomized double-blind treatment period last total four week subject .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<criteria>Written inform consent provide prior conduct studyspecific assessment . Male female adult , 18 65 year age , inclusive . Current diagnosis Social Anxiety Disorder define DSM IV Mental Disorders , secondary another preexist psychiatric condition medical condition . Confirmation diagnosis Social Anxiety Disorder accord MINI , 5.0.0 Clinicianrated Liebowitz Social Anxiety Scale total score ≥60 Screening Baseline visit . Clinicianrated HAMD17 total score &lt; 18 Screening Baseline visit . CGISeverity score ≥4 Screening Baseline visit . Subject must : experience document minimum total six social interaction performance event two week Screening Period prior Baseline Visit , least three event , must achieve peak score ≥60 Subjective Units Distress Scales ( SUDS ) , rat Patient Diary . Women childbearing potential must able commit consistent correct use effective method birth control throughout study negative urine pregnancy test result prior study medication administration . History bipolar disorder ( I II ) , schizophrenia , schizoaffective disorder , psychosis , eat disorder , obsessivecompulsive disorder . Any current Axis I disorder SAD primary focus treatment . Note subject concurrent Generalized Anxiety Disorder ( GAD ) eligible study provide GAD primary diagnosis . Subjects meet criterion substance abuse within year prior entry . Clinically significant nasal pathology history significant nasal trauma , nasal surgery , nasalseptal perforation may damage nasal chemosensory epithelium . An acute chronic condition , include infectious illness , uncontrolled seasonal allergy time study , significant nasal congestion potentially could affect drug delivery nasal chemosensory epithelium . Two document fail treatment trial register medication approve SAD previous six month , whereby treatment trial define period least six ( 6 ) week ( longer document package insert particular drug ) patient receive adequate dosage ( define treatment dose indicated package insert obtain efficacy particular drug ) medication . Use psychotropic medication within 30 day prior study entry ( eszopiclone , ramelteon , zaleplon , zolpidem insomnia describe Section 3.3 ) . Concomitant use nonstudy anxiolytic benzodiazepine beta blocker study within 30 day prior study entry . Concomitant use overthecounter , prescription product , herbal preparation treatment symptom social anxiety study within 30 day prior study entry . Prior exposure PH94B . Improvement 20 % LSAS score Baseline relative Screening . Women positive urine human chorionic gonadotropin pregnancy test prior study medication administration . Subjects clinically significant abnormality hematology , blood chemistry , urinalysis , ECG , physical examination identify Screening Baseline visit . Subjects positive urine drug screen either Screening Baseline visit . Presence clinical condition disease , use concomitant medication , clinical judgment Investigator could place patient undue risk , interfere study participation , confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>Social Phobia</keyword>
	<keyword>Performance Anxiety</keyword>
	<keyword>Social Anxiety</keyword>
	<keyword>Anxiety</keyword>
</DOC>